- Markets - Around The World
- Posts
- AI for Coke's Supply Chain Puzzle
AI for Coke's Supply Chain Puzzle
Diamond Industry's Battle: Natural vs. Lab-Grown
Coca-Cola Japan Taps AI to Fix Its Supply Chain Puzzle
Coca-Cola Bottlers Japan is turning to AI to manage one of the world’s trickiest supply chains. Partnering with o9 Solutions, it's rolling out a “Digital Brain” that organizes real-time data to streamline production and delivery.
The system uses a smart knowledge graph to make better decisions around expiry dates, routing, and local logistics. The result? Faster deliveries, less waste, and lower storage costs.
Beyond efficiency, the move signals a shift toward greener operations. While AI’s energy needs pose a challenge, o9’s focus on clean energy and Coca-Cola’s scale could help drive both sustainability and smarter supply chains.
De Beers vs. Pandora: Contrasting Diamond Market Strategies
Source: Chartr and Google Trends
De Beers is abandoning its lab-grown diamond brand Lightbox after watching wholesale prices plummet 90%, retreating to its natural diamond fortress. Meanwhile, Pandora's CEO Alexander Lacik boldly predicts synthetic diamonds will dominate the market within a decade, with his company's lab-grown sales already surging 88% year-over-year.
De Beers blames Chinese mass production and waning consumer interest for making lab-grown diamonds commercially unviable, with company earnings down a staggering 88%. Pandora sees the exact same price collapse as an opportunity, betting that affordability-not scarcity-will drive the next wave of diamond jewelry consumption.
Source: Chatr
This industry showdown pits De Beers' century-old luxury mystique against Pandora's volume-driven accessibility play in a zero-sum game for consumer preference. The world's most iconic diamond producer and its largest jewelry maker have placed opposite bets on the future, with billions in market value hanging in the balance.
Revolutionizing Cancer Treatment: Precision Therapies on the Horizon
Cancer treatment is getting a major upgrade with precision therapies that go straight after the bad cells, leaving healthy ones mostly untouched. One of the most exciting breakthroughs is CAR-T cell therapy, which reprograms the body’s own immune cells to hunt down cancer.
These treatments are becoming smarter thanks to tools like AI, which help doctors detect cancer earlier and choose the best plan for each patient. It’s no longer just about one-size-fits-all chemo—now it’s about targeting the right cancer, in the person, at the right time.
Biotech and data science are working hand-in-hand to speed up new discoveries and bring them to more people. The result? A future where cancer care is not only more hopeful—but more personal and powerful than ever before.